Knight Therapeutics Acquires Endo's International Pharmaceuticals Business (Paladin Pharma)

Mallinckrodt plc Completes Merger with Endo, Inc.

August 1, 2025

Pharmaceuticals

Mallinckrodt plc and Endo, Inc. have completed a business combination to create a global, scaled therapeutics company, with Endo shareholders receiving cash and a 49.9% pro forma equity stake. The combined company will operate branded therapeutics and a generics/sterile injectables business (to be named Par Health), with Par Health intended to be spun off as an independent company targeted for Q4 2025 to unlock focused growth and realize synergies.

Partners Group Acquires Pharmathen from BC Partners

July 19, 2021

Pharmaceuticals

Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.

Merck Acquires Pandion Therapeutics

February 25, 2021

Biotechnology

Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.

Bayer Acquires UK Biotech KaNDy Therapeutics Ltd.

August 11, 2020

Biotechnology

Bayer has agreed to acquire UK-based clinical-stage biotech KaNDy Therapeutics Ltd. for an upfront $425 million with up to $450 million in additional milestone payments, expanding Bayer's women's healthcare drug development pipeline—specifically the investigational non-hormonal compound NT-814 for menopausal vasomotor symptoms. The acquisition, subject to customary conditions, was announced in August 2020 and is expected to close in September 2020.

J. Knipper and Company Acquires Eagle Pharmacy

November 11, 2020

Healthcare Services

J. Knipper and Company, Inc., together with its affiliate KnippeRx, has acquired Eagle Pharmacy, LLC, a Lakeland, Florida-based direct-to-patient specialty pharmacy. The acquisition expands Knipper's pharmacy programs, automation and scale—Eagle currently supports more than 50 customized drug programs, reaches about 200,000 patients per month, and operates well below capacity.

Eilean Therapeutics Acquires Ness Therapeutics

March 4, 2024

Biotechnology

Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.